Ourania Tatsis - 24 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
24 Feb 2023
Net transactions value
-$1,058,177
Form type
4
Filing time
28 Feb 2023, 16:11:24 UTC
Previous filing
22 Feb 2023
Next filing
14 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $956,409 -3,308 -5.5% $289.12 57,159 24 Feb 2023 Direct
transaction VRTX Common Stock Sale $81,278 -283 -0.5% $287.20 56,876 27 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $14,705 -51 -0.09% $288.33 56,825 27 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $5,786 -20 -0.04% $289.29 56,805 27 Feb 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60).
F4 Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74).
F5 Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40).